PHT Corporation Report issue

For profit Phase 2 Phase 3
Founded: Boston MA United States (1994)
Status: Acquired by ERT Clinical (2015)

Organization Overview

First Clinical Trial
2010
NCT01731249
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

birch allergen (1 trial)

Drugs in Phase 2 Trials (3)

ix-01 (1 trial)

medi-8968 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Hidradenitis (Phase 2)

Hidradenitis Suppurativa (Phase 2)

Hypersensitivity (Phase 3)

Premature Birth (Phase 2)

Premature Ejaculation (Phase 2)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4